Evidence map›Paper›PMID 33519801›Full record

ArticleFrontiers in immunology2020

Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.

Raquel Furtado, Laurent Chorro, Natalie Zimmerman, Erik Guillen, Emily Spaulding, Shu Shien Chin, Johanna P Daily, Grégoire Lauvau

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. The LEF1-LAG3 axis regulates CD4Parasites & vectors · 2026
    Article
  2. T cell exhaustion in parasitic infections.Frontiers in immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Characteristics of splenic PD-1Immunologic research · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. T cell help in the autoreactive germinal center.Scandinavian journal of immunology · 2022
    Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Raquel FurtadoDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Laurent ChorroDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Natalie ZimmermanDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Erik GuillenDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Emily SpauldingDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Shu Shien ChinDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Johanna P DailyDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Grégoire LauvauDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Albert Einstein College of Medicine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6M
Bronx-Einstein Training in Teaching and Research (BETTR), an IRACDA programK12GM102779 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Dianne Cox, Johanna Patricia Daily · 2012 to 2026
$9.2M
Geographic Medicine and Emerging InfectionsT32AI070117 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WEISS, LOUIS M. · 2008 to 2023
$5.1M
Einstein Postbaccalaureate Research Education ProgramR25GM104547 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI AKABAS, MYLES H. · 2013 to 2023
$4.0M
Mechanisms of Plasmacytoid dendritic cell activation in vivoR21AI128735 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI FOOKSMAN, DAVID R, LAUVAU, GREGOIRE STEPHANE · 2017 to 2018
$459k
Cytek Aurora Multiparameter Flow CytometerS10OD026833 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PORCELLI, STEVEN A · 2019 to 2019
$367k
NCI NIH HHS P30 CA013330NIAID NIH HHS R21 AI128735NIAID NIH HHS T32 AI070117NIGMS NIH HHS K12 GM102779NIGMS NIH HHS R25 GM104547NIGMS NIH HHS T32 GM007288NIH HHS S10 OD026833
6 · The paper itself

Abstract

T cells expressing high levels of inhibitory receptors such as PD-1 and LAG-3 are a hallmark of chronic infections and cancer. Checkpoint blockade therapies targeting these receptors have been largely validated as promising strategies to restore exhausted T cell functions and clearance of chronic infections and tumors. The inability to develop long-term natural immunity in malaria-infected patients has been proposed to be at least partially accounted for by sustained expression of high levels of inhibitory receptors on T and B lymphocytes. While blockade or lack of PD-1/PD-L1 and/or LAG-3 was reported to promote better clearance of

Indexed as

AnimalsAntibodies, MonoclonalAntigens, CDB7-H1 AntigenCD4-Positive T-LymphocytesCells, CulturedDisease Models, AnimalHumansImmune Checkpoint InhibitorsImmunity, HumoralLife Cycle StagesLymphocyte Activation Gene 3 ProteinMalaria, FalciparumMaleMiceMice, Inbred C57BLAntibodies, MonoclonalAntigens, CDB7-H1 AntigenImmune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinPdcd1 protein, mouseProgrammed Cell Death 1 Receptorcheckpoint therapeutic blockadehumoral immunityinhibitory receptorsLAG-3+ CD4+ and CD8+ T cellsmalariaPD-1/PD-L1/LAG-3PD-L1 and PD-1 knockout micePlasmodium yoelii

Identifiers

PMID33519801
PMCPMC7840658
OpenAlexW3120410125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.